InMode Ltd vs Lemonade Inc — how do they compare? InMode Ltd trades at $14.2 (market cap $809.93M), while Lemonade Inc trades at $46.44 (market cap $3.63B). The key difference: Lemonade Inc is far larger — about 4.5× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Lemonade Inc for 27 Days on average.
| INMD | LMND | |
|---|---|---|
Market Cap | $809.93M | $3.63B |
Volume | 365,490 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $16.62 | $96.57 |
52-Week Low | $12.76 | $43.91 |
Typical Hold Time | 28 Days | 27 Days |
Enterprise Value | $313.27M | $3.49B |
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.14, up 0.93% on the day, with bearish technical signals from moving averages but attractive valuation metrics including a P/E of 11.63 and EV/EBITDA of 4.48. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while maintaining strong profitability with 76.52% gross margins. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share.
The stock presents value opportunity with solid fundamentals but faces near-term headwinds from cyclical industry softness and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings versus 55% hold, suggesting cautious optimism amid ongoing strategic review of the acquisition proposal.
LMND trades at $46.64, down 0.41% on the day, with a bearish technical signal despite recent earnings beats. Revenue growth remains strong at 32% year-over-year in Q2 2026, with improving loss ratios and gross profit up 76%. The company is expanding geographically and expects its first EBITDA-positive quarter in late 2026, supported by AI-driven efficiency gains.
While LMND shows promising growth and path to profitability, the stock faces headwinds from persistent net losses, high valuation multiples, and mixed analyst sentiment. The consensus price target of $67.00 suggests 44% upside potential, but investors must weigh growth prospects against ongoing cash burn and competitive pressures in the insurtech space.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →